Increases in the Birmingham Vasculitis Activity Score (BVAS) may work as an independent risk predictor for cardiovascular disease (CVD)-related deaths in ANCA-associated vasculitis, a single-center study from China found. The study, “The BVAS is an independent predictor of cardiovascular events and cardiovascular disease-related mortality in patients with…
In patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), Rituxan (rituximab) may lead to general decrease in antibody levels, increasing their risk for infections, finds a single-center retrospective study. The study, “Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis,” appeared in…
The Phase 3 ADVOCATE trial, evaluating ChemoCentryx‘s investigational drug avacopan (formerly CCX168) for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is now enrolling participants. The update is part of the company’s financial report for the second quarter of 2017. The study (NCT02994927), which aims to evaluate the safety…
Get regular updates to your inbox.